Lyka LabsBOM:500259 +0.78%60 Interest Coverage is 0 (At Loss) as of Mar. 2026. GuruFocus rates BOM:500259 with a GF Score™ of 60/100 and a GF Value™ of ₹127.26 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 376 Biotechnology companies, Lyka Labs ranks worse than 265957.18% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Lyka Labs's
Operating Income
for the
three
months ended in Mar. 2026 was ₹-85 Mil. Lyka Labs's Interest Expense for the
three
months ended in Mar. 2026 was ₹-7 Mil.
did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Lyka Labs's Interest Coverage or its related term are showing as below:
BOM:500259's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 104.025 * Ranked among companies with meaningful Interest Coverage only.
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Lyka Labs Interest Coverage Related Terms
Lyka Labs Interest Coverage Historical Data
* Premium members only.
The historical data trend for Lyka Labs's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
BOM:500259 vs VRTX, REGN, ALNY: Interest Coverage Comparison
For the Biotechnology subindustry, Lyka Labs's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lyka Labs Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lyka Labs's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Lyka Labs's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Lyka Labs did not have earnings to cover the interest expense.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Coverage of 0 (At Loss) mean?
Lyka Labs (BOM:500259) has a Interest Coverage of 0 (At Loss) as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Lyka Labs and its competitors. According to the industry distribution chart, Lyka Labs ranks #999999 out of 376 companies in the Biotechnology industry.
Is Lyka Labs' Interest Coverage too high?
Lyka Labs' current Interest Coverage is 0 (At Loss). Based on the distribution chart, Lyka Labs ranks #999999 out of 376 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lyka Labs has a GF Score™ of 60/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lyka Labs' Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lyka Labs ranks #999999 out of 376 companies for Interest Coverage. This places Lyka Labs in the lower half of its industry. The industry median Interest Coverage is 104.03. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 104.03, based on 376 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Lyka Labs and its competitors. For the Biotechnology industry, the median Interest Coverage is 104.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lyka Labs's current Interest Coverage is 0 (At Loss). However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lyka Labs stock overvalued right now?
Based on GuruFocus' analysis, Lyka Labs (BOM:500259) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹127.26, compared to a current price of ₹72.36 — trading 43.1% below its estimated fair value. The current Interest Coverage is 0 (At Loss). Lyka Labs' overall GF Score™ is 60/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Lyka Labs (BOM:500259), the current Interest Coverage is 0 (At Loss) as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lyka Labs (BOM:500259) Overvalued in 2026?
Based on GuruFocus' analysis, Lyka Labs stock appears to be undervalued.
The current stock price of ₹72.36 is trading 43.1% below its estimated GF Value™ of ₹127.26.
GuruFocus considers Lyka Labs to be Significantly Undervalued.
Key valuation signals for BOM:500259:
Interest Coverage: 0 (At Loss)
GF Value™: ₹127.26 vs. price of ₹72.36 (43.1% below fair value)
No single metric tells the full story. See the BOM:500259 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lyka Labs Ltd is an Indian biotechnology company. It mainly engages in the development of specialized formulations. The Company is engaged in only one segment which is pharmaceuticals. The Company has a presence in Domestic as well as International markets. The commercialized formulations of the company consist of hair care, anti-aging, acne management, skin lightening, face washes, sunscreens, facial scrubs, and others. It has developed a varied drug delivery system for topical steroids, painkillers, anti-fungal, and other emollients as well as liquid injectables, lyophilized injectables in the anti-bacterial, antifungal segment. The company also manufactures proton pump inhibitors, antibiotics, antifungals, steroids, etc. The majority of the company's revenue comes from India.
60GF Score
Get the complete analysis for BOM:500259
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:500259 has been successfully added to your 
